Showing results (11-20 of 105) with videos related to
Sort By:
Pageof 11
Biopharmaceutics & Drug Disposition|October 14, 2015
Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applicationsGregory Z Ferl, Frank-Peter Theil, Harvey WongJournal of Pharmaceutical Sciences|March 26, 2018
Exploring a Kinetic Model Approach in Biopharmaceutics: Estimating the Fraction Absorbed of Orally Administered Drugs in HumansPo-Chang Chiang, Jia Liu, Peter Fan, et al.Molecular Pharmaceutics|April 25, 2013
Systemic concentrations can limit the oral absorption of poorly soluble drugs: an investigation of non-sink permeation using physiologically based pharmacokinetic modelingPo-Chang Chiang, Hank La, Haiming Zhang, et al.Cancer Chemotherapy and Pharmacology|June 27, 2024
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancerAnita Moein, Jin Y Jin, Matthew R Wright, et al.Journal of Clinical Pharmacology|April 19, 2024
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor)Anita Moein, Jin Y Jin, Matthew R Wright, et al.Journal of Pharmaceutical Sciences|January 6, 2026
A multicompartment stomach physiologically-based pharmacokinetic model capturing gastric reacidification can improve food effect predictions of weak basesLisa Cheng, Po-Chang Chiang, Matthew R Wright, et al.Drugs in R&D|May 3, 2024
Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR InhibitorAnita Moein, Jin Y Jin, Matthew R Wright, et al.Nanoscale Research Letters|June 30, 2011
Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug deliveryPo-Chang Chiang, Yingqing Ran, Kang-Jye Chou, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2022
Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of VismodegibLouis Lin, Matthew R Wright, Cornelis E C A Hop, et al.The Journal of Pharmacology and Experimental Therapeutics|April 28, 2011
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacyLichuan Liu, Julie Di Paolo, Jim Barbosa, et al.Pageof 11